P

Poolbeg Pharma PLC
LSE:POLB

Watchlist Manager
Poolbeg Pharma PLC
LSE:POLB
Watchlist
Price: 7.105 GBX -0.63% Market Closed
Market Cap: 35.5m GBX
Have any thoughts about
Poolbeg Pharma PLC?
Write Note

Poolbeg Pharma PLC
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Poolbeg Pharma PLC
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
P
Poolbeg Pharma PLC
LSE:POLB
Retained Earnings
-ÂŁ8.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GlaxoSmithKline PLC
LSE:GSK
Retained Earnings
ÂŁ9.6B
CAGR 3-Years
-4%
CAGR 5-Years
N/A
CAGR 10-Years
17%
AstraZeneca PLC
LSE:AZN
Retained Earnings
$3.9B
CAGR 3-Years
-19%
CAGR 5-Years
-6%
CAGR 10-Years
-14%
Verona Pharma PLC
NASDAQ:VRNA
Retained Earnings
-$528.5m
CAGR 3-Years
-30%
CAGR 5-Years
-39%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Retained Earnings
$2.3B
CAGR 3-Years
2%
CAGR 5-Years
6%
CAGR 10-Years
11%
Dechra Pharmaceuticals PLC
LSE:DPH
Retained Earnings
ÂŁ171m
CAGR 3-Years
-7%
CAGR 5-Years
6%
CAGR 10-Years
15%
No Stocks Found

Poolbeg Pharma PLC
Glance View

Market Cap
35.5m GBX
Industry
Pharmaceuticals

Poolbeg Pharma Plc is a clinical-stage infectious disease pharmaceutical company. The firm is focused on targeting the medical needs to treat and prevent infectious disease. The firm's portfolio includes POLB 001, Vaccine Discovery Platform, PredictViral Biomarker Platform, and disease progression data and bio banks. The firm's lead product pipeline candidate is POLB 001. POLB 001 is a Phase II ready p38 mitogen-activated protein kinase (MAPK) inhibitor that reduces harmful inflammation (cytokine storm) in patients with severe influenza. POLB 001 is a repositioned small molecule immunomodulator for severe influenza. The firm is developing a PredictViral biomarker platform, which is used to identify those at risk of developing severe disease. The Vaccine Discovery Platform is a platform used to identify vaccine candidates by isolating protective elements of the naturally occurring immune response.

POLB Intrinsic Value
2.434 GBX
Overvaluation 66%
Intrinsic Value
Price
P

See Also

What is Poolbeg Pharma PLC's Retained Earnings?
Retained Earnings
-8.8m GBP

Based on the financial report for Dec 31, 2023, Poolbeg Pharma PLC's Retained Earnings amounts to -8.8m GBP.

What is Poolbeg Pharma PLC's Retained Earnings growth rate?
Retained Earnings CAGR 1Y
-80%

Over the last year, the Retained Earnings growth was -80%.

Back to Top